Key Takeaways
- Bayer (BAYN) is making significant strides in Parkinson's disease treatment, advancing both cell and gene therapies to Phase III and Phase II trials, respectively. The company also anticipates its heart drug Beyonttra to become an unexpected blockbuster candidate, with European approval already secured and a commercialization agreement with BridgeBio Pharma (BBIO) in Europe.
- The highly anticipated TikTok deal is moving closer to finalization, with Oracle (ORCL) poised to secure the app's algorithm and President Trump expected to sign an Executive Order approving the deal later this week, addressing national security concerns.
- Meta (META) is actively pushing for the accelerated adoption of its Llama AI models within the U.S. Government, emphasizing that its open-source models are accessible without procurement talks or restrictions.
Bayer (BAYN) is making significant advancements in its pharmaceutical pipeline, particularly in the challenging field of neurological disorders and cardiovascular health. The German pharmaceutical giant has become the first company to advance both cell therapy and gene therapy candidates against Parkinson’s disease into later-stage clinical trials. Its investigational cell therapy, bemdaneprocel, is entering a pivotal Phase III clinical trial, while its gene therapy candidate, AB-1005, is progressing into a Phase II study. This dual approach highlights Bayer's commitment to addressing the root causes of Parkinson's, a disease that has seen little fundamental therapeutic change in decades.
In other positive news for Bayer's pharmaceutical division, its heart drug Beyonttra (acoramidis) is emerging as an unexpected blockbuster candidate. The drug, which treats transthyretin amyloid cardiomyopathy (ATTR-CM), has already received marketing authorization in the European Union. Bayer has a commercialization agreement with BridgeBio Pharma (BBIO) for Beyonttra in Europe, with the drug expected to challenge Pfizer's (PFE) dominance in the ATTR-CM market.
Meanwhile, the contentious TikTok deal appears to be nearing a resolution, with President Trump expected to sign an Executive Order approving the agreement later this week. This approval would confirm that the deal meets legal requirements, following months of negotiations driven by national security concerns regarding the app's Chinese ownership. Oracle (ORCL) is slated to play a critical role, securing TikTok's algorithm and ensuring data privacy and security for its U.S. users. Under the proposed deal, Oracle will reportedly retrain the U.S. version of TikTok's content algorithm and oversee user data, with American entities controlling the algorithm and holding a majority of board seats for the app's U.S. operations. The deal aims to ensure that foreign powers, specifically China, cannot access U.S. user data or manipulate content.
In the realm of artificial intelligence, Meta (META) is actively engaging with the U.S. Government to promote the faster adoption of its AI technologies. The company states that, unlike traditional government agreements requiring extensive procurement talks, its arrangement demands no such discussions because its Llama models are accessible without restrictions. Meta's strategy involves making its open-source Llama models available to various U.S. government agencies, including those involved in defense and national security applications, and to private sector partners supporting their work. This initiative aims to leverage advanced AI capabilities to enhance the efficiency and effectiveness of government operations.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.